Brief: Alumis And Acelyrin To Merge Creating A Late-Stage Clinical Biopharma Company

Alumis

06/02/2025 23:12

Feb 6 (Reuters) - Alumis Inc  ALMS.O :
    * ALUMIS AND ACELYRIN TO MERGE CREATING A LATE-STAGE
CLINICAL
BIOPHARMA COMPANY DEDICATED TO INNOVATING, DEVELOPING AND
COMMERCIALIZING TRANSFORMATIVE THERAPIES FOR IMMUNE-MEDIATED
DISEASES
    * ALUMIS INC: ALUMIS & ACELYRIN STOCKHOLDERS TO OWN ABOUT
55% &
ABOUT 45%, RESPECTIVELY, OF COMBINED CO ON FULLY DILUTED BASIS
    * ALUMIS INC: COMBINED COMPANY WILL OPERATE UNDER ALUMIS
NAME WITH
CURRENT ALUMIS EXECUTIVE TEAM
    * ALUMIS INC: UNDER DEAL, ACELYRIN STOCKHOLDERS TO RECEIVE
0.4274
SHARES OF ALUMIS COMMON STOCK FOR EACH SHARE OF ACELYRIN COMMON
STOCK OWNED
    * ALUMIS INC: ALUMIS & ACELYRIN'S COMBINED PRO FORMA CASH
POSITION
OF ABOUT $737 MILLION AS OF DEC 31, 2024, PROVIDES RUNWAY INTO
2027

Source text:  ID:nGNX17Bc7f 
Further company coverage:  ALMS.O 

 ((reuters.briefs@thomsonreuters.com;))